São Paulo, May 2019 –Eurofarma, 100% Brazilian capital pharmaceutical company, present in 20 countries in Latin America, already makes available for the Brazilian Market the medicine Prysma® (eszopiclone), which contemplates an innovating, inedited molecule for insomnia treatment approved by the Brazilian Sanitary Surveillance Agency (Agência Nacional de Vigilância Sanitária – Anvisa).


The commercialization of Prysma®, which has shown to be efficient and safe in adult patients who have difficulty in falling to sleep or staying asleep, guaranteeing up to 8 hours of rest, started in 2019.


In studies done with patients with various kinds of insomnia – including chronic – adults, women and elderly who also presented insomnia associated with psychological disorders, such as anxiety and depression, the medication proved to be efficient in the improvement of sleep parameters and performance in daily activities, associated with better sleep quality and greater feeling of well-being. Besides this, they not experience clinical problems related to addiction, rebound effect or development of tolerance with long-term use.


In Brazil, a phase III clinical study was done and Prysma® (eszopiclone) presented greater total time and great sleep efficiency when compared to another medication for insomnia, with a similar safety profile.


According to the Brazilian Sleep Association, it is estimated that more than 70 million Brazilian have repetitive difficulty in starting to sleep or staying asleep, which may cause bad moods, irritability, low productivity, memory problems and fatigue.


“The launch of Prysma® inaugurates the first category of Anvisa being a diverse innovative medicine and is the only one of the 3rd generation of sleep inducers in Brazil, offering doctors and their patients an option for up to 8 hours of sleep that does not cause addiction and with fewer side effects than benzodiazepines,”  explains Roberta Junqueira Nóbrega, Commercial Director of Eurofarma’s Medical Prescription Unit.


About Grupo Eurofarma

The Grupo Eurofarma is a health company, focused on offering products and services to improve people’s lives with quality, innovation and fair price in the areas of Medical Prescription, Over-the-counter, Generic, Hospital, Oncology and Veterinary. In Brazil alone, the company offers 287 products in 622 presentations, serves 30 medical specialties and covers 101 therapeutic classes, which represent 89% of pharmaceutical retail sales.


Founded in 1972 and the first multinational pharmaceutical company with 100% Brazilian capital, it has its own operations in 20 countries, maintaining an important industrial park in Brazil and plants in 6 other Latin American countries. In 2018, the group generated sales of R$4.3 billion and employs more than 6.7 thousand employees.


For further information, access www.eurofarma.com.br

Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram:@eurofarma_br


Press information:


G&A – Public Relations

André Pascowitch – 11 5090-8600 r.8646 – andre@gaspar.com.br

Guilherme Gaspar – Tel. 11 3065-3045 – guilherme@gaspar.com.br